Dianthus Therapeutics to Showcase Innovations at Two Investor Events
Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a pioneering clinical-stage biotechnology company focusing on groundbreaking antibody complement therapeutics for severe autoimmune diseases, has announced exciting participation at two forthcoming investor gatherings. With a mission centered on innovative treatments, Dianthus is eager to connect with potential investors and present its unique approach to addressing these challenging conditions.
Upcoming Investor Events
Baird Biotech Discovery Series
Marino Garcia, the Chief Executive Officer of Dianthus Therapeutics, is scheduled to engage in a fireside chat webcast on an important platform, Baird Biotech Discovery Series. This interactive session is set for May 6 at 1:30 PM EDT. Attendees can anticipate valuable insights into the company’s strategic vision and therapeutic developments.
Bank of America 2025 Health Care Conference
Later in the month, Marino Garcia will deliver a corporate overview during the Bank of America 2025 Health Care Conference on May 14, at 5:35 PM EDT / 2:35 PM PDT. Following the presentation, he will be available for one-on-one meetings with investors, facilitating deeper discussions about the company’s prospects and research advancements.
Webcasts Available for Access
For those unable to attend these sessions live, webcasts of the presentations will be accessible. Interested parties can find these under the "News and Events" section of the Dianthus Therapeutics website, ensuring that no one misses the opportunity to engage with the insights provided during these key events.
About Dianthus Therapeutics
Dianthus Therapeutics is dedicated to revolutionizing the treatment of severe autoimmune and inflammatory diseases through the development of best-in-class monoclonal antibodies that offer improved selectivity and potency. Headquartered in New York City and Waltham, Massachusetts, the company boasts a team of seasoned biotech and pharmaceutical experts, all committed to leading innovation in antibody complement therapeutics.
Through their dedicated efforts, Dianthus aims to provide transformative medicines for individuals suffering from conditions that require advanced treatment options. The company's focus on clinical-stage research positions them at the forefront of biomedical innovation, promising to deliver impactful solutions for complex health issues.
Contact Information
For further inquiries, please reach out to Jennifer Davis Ruff at Dianthus Therapeutics via email at jdavisruff@dianthustx.com.
Frequently Asked Questions
1. What is Dianthus Therapeutics focused on?
Dianthus Therapeutics is focused on developing advanced antibody complement therapeutics aimed at treating severe autoimmune diseases.
2. Who will represent Dianthus at the investor events?
Marino Garcia, the Chief Executive Officer, will represent Dianthus Therapeutics at the investor events.
3. When are the upcoming investor events?
The Baird Biotech Discovery Series is on May 6, and the Bank of America 2025 Health Care Conference is on May 14.
4. How can I access the webcasts of these presentations?
The webcasts will be available in the "News and Events" section of the Dianthus Therapeutics website.
5. How can I get in touch with Dianthus Therapeutics?
You can contact Jennifer Davis Ruff via email at jdavisruff@dianthustx.com.
